Entity

Nuage Therapeutics

Biotechnology - Therapeutics and Diagnostics

Nuage Therapeutics (Nuage Tx) is a spin-off company from the Institute for Research in Biomedicine (IRB Barcelona) and ICREA, that stemmed from the Laboratory of Molecular Biophysics lead by Dr. Xavier Salvatella. Nuage Tx is pioneering a whole new type of drug discovery, unlocking the druggability of intrinsically disordered proteins to deliver a new wave of transformative therapies. Nuage Tx has developed a novel set of tools that enables the reconstitution of intrinsically disordered proteins in a transiently druggable form that renders them amenable to small molecule drug discovery. This ground-breaking approach is initially being deployed to target transcription factors that are key to the growth of specific cancers, which could revolutionise the way that certain tumour types are treated.

 

Nuage Tx has the expertise of Stuart Hughes as CEO; and of its three scientific founders: Dr. Xavier Salvatella; Dr. Denes Hnisz, leader of the Precision Gene Control group at the Max Planck Institute for Molecular Genetics in Berlin; and Dr. Mateusz Biesaga, Nuage’s CTO. Nuage’s team also includes Dr. Jordina Guillén as Head of Science and Olivier Corminboeuf as Head of Drug Discovery.

contact@nuagetx.com

nuagetx.com


Contact person: Júlia Pi López

Location: Torre I - 08A1